Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZEBOV booster in HIV-positive adults previously vaccinated against Ebola
PACTR202102747294430Phase 2Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of zabdeno in Ebola virus disease (EVD), sponsored by London School of Hygiene & Tropical Medicine. Started Mar 2021; status: completed.
02
Drugs
zabdeno
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202102747294430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102747294430.